RxDoctor Payments Data

Nsume Eseme, NP

Family · Cleburne, TXNPI 1649983248

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 106 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • AstraZeneca$310
  • Dexcom, Inc.$154
  • Otsuka America Pharmaceutical, Inc.$151
  • Pfizer$127
  • Lilly USA, LLC$119
  • plus $904 from 18 others

What the payments were for

  • Food & beverage$2,09498%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,134 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$2,680
Medicare patients
28
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,482
JardianceEmpagliflozin18$20,973
OzempicSemaglutide15$16,088
VraylarCariprazine Hcl11$15,206
Albuterol Sulfate HfaAlbuterol Sulfate35$989
Alprazolam86$614
Rosuvastatin Calcium26$540
Acetaminophen-CodeineAcetaminophen With Codeine18$519
Gabapentin28$491
Pregabalin30$477
Clindamycin Hcl13$418
FenofibrateFenofibrate Nanocrystallized12$329
Levothyroxine Sodium31$314
Tramadol Hcl42$291
Montelukast Sodium19$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$64$20,97318 claims
Novo NordiskOzempic$83$16,08815 claims
AbbVieVraylar$370$15,20611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →